Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP652086.RAulyTRo95BP3pV-Tleug31MOddtCuPwxRTk_gl_ZDHl8130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP652086.RAulyTRo95BP3pV-Tleug31MOddtCuPwxRTk_gl_ZDHl8130_assertion type Assertion NP652086.RAulyTRo95BP3pV-Tleug31MOddtCuPwxRTk_gl_ZDHl8130_head.
- NP652086.RAulyTRo95BP3pV-Tleug31MOddtCuPwxRTk_gl_ZDHl8130_assertion description "[The subjects were 1,471 breast cancer patients who had been evaluated for HER2 expression between 1998 and March 2006; 74 of these had recurrent breast cancer that had been treated with trastuzumab.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP652086.RAulyTRo95BP3pV-Tleug31MOddtCuPwxRTk_gl_ZDHl8130_provenance.
- NP652086.RAulyTRo95BP3pV-Tleug31MOddtCuPwxRTk_gl_ZDHl8130_assertion evidence source_evidence_literature NP652086.RAulyTRo95BP3pV-Tleug31MOddtCuPwxRTk_gl_ZDHl8130_provenance.
- NP652086.RAulyTRo95BP3pV-Tleug31MOddtCuPwxRTk_gl_ZDHl8130_assertion SIO_000772 18224396 NP652086.RAulyTRo95BP3pV-Tleug31MOddtCuPwxRTk_gl_ZDHl8130_provenance.
- NP652086.RAulyTRo95BP3pV-Tleug31MOddtCuPwxRTk_gl_ZDHl8130_assertion wasDerivedFrom befree-2016 NP652086.RAulyTRo95BP3pV-Tleug31MOddtCuPwxRTk_gl_ZDHl8130_provenance.
- NP652086.RAulyTRo95BP3pV-Tleug31MOddtCuPwxRTk_gl_ZDHl8130_assertion wasGeneratedBy ECO_0000203 NP652086.RAulyTRo95BP3pV-Tleug31MOddtCuPwxRTk_gl_ZDHl8130_provenance.